FDA News

FDA Accepts Pozen Response on Trexima

(March 22, 2007)--POZEN announced the amended response to a previous FDA approvable letter for Trexima has been accepted for review by the U.S. Food and Drug Administration (FDA). Trexima is the proposed brand name for the combination of sumatriptan succinate, formulated with RT Technology, and naproxen sodium, in a single tablet for the acute treatment of migraine. The FDA has also notified POZEN that it expects a Class II review (six months), which could result in a new decision date of August 1, 2007. Pending FDA approval, the product could be available to patients in the second half of 2007.

Migraine affects more than 28 million people in the Unites States alone, of which roughly three out of four migraine sufferers are women. According to the International Headache Society's diagnostic criteria, migraine is characterized by recurrent headaches lasting 4 to 72 hours (untreated) and with symptoms including moderate to severe headache pain, which is typically throbbing, unilateral, and aggravated by routine activity, nausea, vomiting, and sensitivity to light and sound. Migraine can be disabling and sufferers may miss work, lose time with family and friends, and be unable to pursue basic daily activities.

Share or bookmarklet this web page at: